Methylation and expression profiles of MGMT gene in thymic epithelial tumors

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 279-287

  Mokhtar, Mohamed ^a,b   Kondo, Kazuya ^a   Namura, Toshiaki ^a   Ali, Abdellah H K ^c   Fujita, Yui ^a   Takai, Chikako ^a   Takizawa, Hiromitsu ^a   Nakagawa, Yasushi ^a   Toba, Hiroaki ^a   Kajiura, Koichiro ^a   Yoshida, Mitsuteru ^a   Kawakami, Gyokei ^a   Sakiyama, Shoji ^a   Tangoku, Akira ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Department of Oncological Surgery   (Egypt)

^c Sohag University   (Egypt)

Author keywords

DNA methylation; Gene silencing; Thymic carcinoma; Thymic epithelial tumors; Thymoma

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PRACTICE; DNA METHYLATION; DNA REPAIR; EPITHELIUM TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMIC EPITHELIAL TUMOR; THYMOMA; THYMUS CANCER; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT;

DNA METHYLATION; GENE SILENCING; M; METHYLATED; METHYLATION INDEX; METHYLATION-SPECIFIC PCR; MG; MGMT; MI; MSP; MYASTHENIA GRAVIS; NI; NON-INFORMATIVE CASE; O(6)-METHYLGUANINE DNA METHYLTRANSFERASE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TET; THYMIC CARCINOMA; THYMIC EPITHELIAL TUMORS; THYMOMA; U; UNMETHYLATED; WHO; WORLD HEALTH ORGANIZATION;

ADULT; AGED; CARCINOGENESIS; CARCINOMA; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROMOTER REGIONS, GENETIC; THYMOMA; THYMUS NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84892877225     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.12.004     Document Type: Article

References (37)

1. Girard N., Mornex F., Van Houtte P., Cordier J.F., van Schil P. Thymoma: a focus on current therapeutic management. J Thorac Oncol 2009, 4:119-126.
2. Girard N. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 2010, 5:S291-S295.
3. Girard N., Shen R., Guo T., Zakowski M.F., Heguy A., Riely G.J., et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009, 15:6790-6799.
4. Girard N., Teruya-Feldstein J., Payabyab E.C., Riely G.J., Rusch V.W., Kris M.G., et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 2010, 5:1439-1446.
5. Breinig M., Mayer P., Harjung A., Goeppert B., Malz M., Penzel R., et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res 2011, 17:2237-2249.
6. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005, 45:629-656.
7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298.
8. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
9. Szyf M. Targeting DNA methylation in cancer. Ageing Res Rev 2003, 2:299-328.
10. 6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 2002, 24:255-266.
11. Ludlum D.B. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 1990, 233:117-126.
12. Erickson L.C., Laurent G., Sharkey N.A., Kohn K.W. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 1980, 288:727-729.
13. Hirose Y., Kondo K., Takizawa H., Nagao T., Nakagawa Y., Fujino H., et al. Aberrant methylation of tumour-related genes in thymic epithelial tumours. Lung Cancer 2009, 64:155-159.
14. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO classification of tumours 2004, 145-197. IRAQ Press, Lyon.
15. Masaoka A., Monden Y., Nakahara K., Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981, 48:2485-2492.
16. Kondo K., Takahashi Y., Hirose Y., Nagao T., Tsuyuguchi M., Hashimoto M., et al. The reduced expression and aberrant methylation of p16(INK4a) in chromate workers with lung cancer. Lung Cancer 2006, 53:295-302.
17. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93:9821-9826.
18. 6-methylguanine-DNA methyltransferase gene. Cancer Res 1997, 57:3672-3677.
19. House M.G., Guo M., Iacobuzio-Donahue C., Herman J.G. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003, 24:193-198.
20. 6-methylguanine-DNA methyltransferase expression in human lung carcinomas. Carcinogenesis 1998, 19:1247-1250.
21. Kondo K., Yoshizawa K., Tsuyuguchi M., Kimura S., Sumitomo M., Morita J., et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 2004, 77:1183-1188.
22. Detterbeck F.C., Parsons A.M. Thymic tumors. Ann Thorac Surg 2004, 77:1860-1869.
23. Hino N., Kondo K., Miyoshi T., Uyama T., Monden Y. High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer 1997, 76:1361-1366.
24. Zettl A., Strobel P., Wagner K., Katzenberger T., Ott G., Rosenwald A., et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000, 157:257-266.
25. Zhou R., Zettl A., Strobel P., Wagner K., Muller-Hermelink H.K., Zhang S., et al. Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol 2001, 159:1853-1860.
26. Inoue M., Starostik P., Zettl A., Strobel P., Schwarz S., Scaravilli F., et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003, 63:3708-3715.
27. Suzuki M., Chen H., Shigematsu H., Ando S., Iida T., Nakajima T., et al. Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol Rep 2005, 14:1621-1624.
28. Hirabayashi H., Fujii Y., Sakaguchi M., Tanaka H., Yoon H.E., Komoto Y., et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997, 73:639-644.
29. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59:793-797.
30. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004, 23:1-8.
31. Bestor T.H. Gene silencing. Methylation meets acetylation. Nature 1998, 393:311-312.
32. Jacinto F.V., Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair 2007, 6:1155-1160.
33. Chen C., Yin B., Wei Q., Li D., Hu J., Yu F., et al. Aberrant DNA methylation in thymic epithelial tumors. Cancer Invest 2009, 27:582-591.
34. Jeremy R.J.R.J. Colorectal cancer: a multipathway disease. Crit Rev Oncog 2006, 12:273-287.
35. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
36. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26:4189-4199.
37. Esteller M., Gaidano G., Goodman S.N., Zagonel V., Capello D., Botto B., et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002, 94:26-32.